Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.30p +17.65% 2.00p 2,349,975 15:32:30
Bid Price Offer Price High Price Low Price Open Price
1.90p 2.10p 2.125p 1.75p 1.75p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.5 -0.3 -0.1 - 5.63

Feedback (FDBK) Latest News (1)

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback (FDBK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
23/6/2018
09:20
Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 1.70p.
Feedback Plc has a 4 week average price of 1.68p and a 12 week average price of 1.20p.
The 1 year high share price is 3.63p while the 1 year low share price is currently 1.20p.
There are currently 281,616,584 shares in issue and the average daily traded volume is 2,018,240 shares. The market capitalisation of Feedback Plc is £5,632,331.68.
20/6/2018
19:48
lr2: Yes, I'm OK. Angry about the probable botched placing but have no problems with the quality of TexRAD. Funny how it took 12 months for Trevor Brown to collapse the share price but only 2 weeks for the BoD to do much the same. Hopefully they can regain some shareholder trust before too long.
18/6/2018
14:13
ashtree2: Bot..thanks for that.The effect on the share price has possibly been worse than if there had been a placing at a significant discount.I would hate to think that this was done on purpose?
14/6/2018
16:03
lr2: I believe the people who gained shares in the last placing are primarily the sellers now as they can likely bank a profit and load up again at the new placing price which looks an odds on certainty to be below 2p by a fair margin. I'm not at all happy with the BoD right now, they had the opportunity to issue a further 46,938,800 under the existing right to issue shares even without contemplating a rights issue to existing shareholders. No warning RNS needed so no wholesale price destruction either. The share price on the day before the General Meeting RNS was 2.8p. If they had issued then, even at a highly discounted 2.5p they would have raised £1.17 million. Let's see what gets raised next time around. The price they raise at is likely to be 1.75p at the rate this share is falling, maybe less. At 1.75p, they will need to use 67,055,430 to achieve the same result. That almost 21 million more shares for no more money. To save themselves from looking like prize pumpkins I would suggest the board will offer even more shares as a saving face exercise. If the board are active investors in this new placing then it looks just a little bit like trading on inside knowledge to me. Time will tell how close I am to being correct.
13/6/2018
11:49
lr2: Yes, but by indicating another money raising they've made it a lot harder for the share price in the short term. I don't blame the board as much as I do Trevor Brown. He decimated the share price by his pernicious selling over the previous 12 months. The board opted to raise a minimal amount at the very low price caused by Trevor Brown but they could have raised some more money (they still had the authority to do so) without calling for a special meeting. That is where, perhaps, they went wrong. Once the market was forewarned of a another likely raising lots of people sold up and pushed the share price downwards. And that is why the share price is where it is. When the clinical version of TexRAD sees light of day, that's when the share price lifts off.
12/6/2018
14:20
soundmanshane: Lots of big moves today pushes share price down ?
27/5/2018
07:39
hughmar: What impact do you think Physiomics plc will have on the share price of Feedback if any? Physiomics plc launch 31st May 2018 doing similar work Physiomics' Virtual Tumour is a sophisticated computer model that simulates tumour cell division and predicts the effect of different anti-cancer regimes to support pre-clinical and clinical oncology development programs. Virtual Tumour helps customers to balance efficacy and toxicity and to prioritise the most effective drug combinations while reducing time and cost.
25/5/2018
11:30
lr2: Agree Brook, if the new guy is willing to pay 3.5p then the share price has plenty of road still to travel.
25/5/2018
11:24
lr2: Well, I hope you enjoy the ride. I've been here awhile now and have no intention of leaving until the share price is significantly higher. I reckon there is so much more to come.
30/4/2018
17:26
tidy 2: SMALL CAP SHARE IDEAS: Heavyweight connections point way forward for medical imaging firm FeedbackGaneshan, who heads the company's medical imaging arm, carried out a study of patients with liver cancer using TexRAD, but impressed by the results Riddell saw wider scale potential.'It quickly dawned on me that this could be a really valuable objective tool for giving an accurate prognosis.'It is in lung cancer that Feedback is now starting to make serious headway.Riddell took over the chair two years ago, but crucial to the recent change of tempo was the award of the European standard CE mark for TexRAD Lung as a diagnosis tool in November.The CE mark means TexRAD Lung can now be sold to hospitals, where it will give numerical support to the work carried out by radiologists.A new chief executive, David Crabb, a software specialist, was recruited in February to spearhead the sales drive for TexRAD.Meanwhile, a tie-up with a company in Poland called Future Processing provides Feedback with the coding know-how to develop a wider product suite.Riddell says the ambition is to move from a company growing modestly to one that will be 'significantly growing'.Feedback's TexRAD texture analysis software can now be sold to hospitals, where it will give numerical support to the work carried out by radiologistsFeedback's TexRAD texture analysis software can now be sold to hospitals, where it will give numerical support to the work carried out by radiologistsSales in the half-year to November were just £229,000 while losses rose to £337,000, so there is plenty to go for.Before the award of the CE mark, the target market was individual research hospitals, now Feedback is going for distribution deals (such as the GEHC one) and major manufacturers such as Philips and Siemens.The 40 per cent jump in the share price on the GE deal news highlights the potential if more deals can be agreed.At 2.75p, Feedback is valued at just £7million and for a company with a CE Mark/European approval for lung cancer imaging it is a modest valuation, especially with the development of new treatments for the disease.As Riddell says: 'That's maybe one of the reasons Simon [Sturge] joined the board.'Feedback also has another product in its stable: an imaging archiving system Cadran that was pioneered by the Royal Papworth Hospital.Papworth has just signed a contract for another two years but Riddell believes there is scope to push Cadran out to a much larger audience.Cadran is not subject to the same regulatory regime as TexRAD, but is a vital part of medical imaging, allowing scans to be easily stored, retrieved and analysed to help diagnosis.Slow burn is probably a fair way to describe the company's progress so far even if the technology is impressive.Undoubtedly given its modest size there's an element of risk attached for investors but Riddell is confident Feedback is starting to move forward.'We have a strong board, good products and there is a huge opportunity to take advantage of our connections in the industry.'In TexRAD and Cadran we have a couple of hidden gems, now we have to burnish them and show them to the world.'
27/2/2018
17:54
lr2: Revenue for the half year was £229k but expectation for 2nd half of year is better so perhaps they will manage £500k+ for full year. Not enough to go without more financing but perhaps not a placing with the share price so weak. Some form of short term bank financing might be considered if share price remains weak and clinical sales come in soon. Whilst a placing is always likely it is not the only option. Probably won't have long to wait to find out the answer as to which way they will go.
Feedback share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180623 21:38:58